Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

ABEO | Abeona Therapeutics Inc

Index	-	P/E	-	EPS (ttm)	-3.00	Insider Own	9.49%	Shs Outstand	24.76M	Perf Week	6.07%
Market Cap	99.54M	Forward P/E	-	EPS next Y	-1.77	Insider Trans	0.19%	Shs Float	22.41M	Perf Month	2.29%
Income	-36.37M	PEG	-	EPS next Q	-0.53	Inst Own	40.44%	Short Float / Ratio	2.23% / 3.67	Perf Quarter	-13.92%
Sales	3.57M	P/S	27.88	EPS this Y	55.65%	Inst Trans	27.38%	Short Interest	0.50M	Perf Half Y	47.79%
Book/sh	0.44	P/B	9.24	EPS next Y	27.83%	ROA	-74.02%	Target Price	21.50	Perf Year	32.67%
Cash/sh	1.50	P/C	2.68	EPS next 5Y	-	ROE	-247.16%	52W Range	2.19 - 5.80	Perf YTD	30.52%
Dividend	-	P/FCF	-	EPS past 5Y	19.64%	ROI	-265.06%	52W High	-30.69%	Beta	1.30
Dividend %	-	Quick Ratio	4.67	Sales past 5Y	7.06%	Gross Margin	-7.06%	52W Low	83.56%	ATR	0.31
Employees	57	Current Ratio	4.67	Sales Q/Q	250.00%	Oper. Margin	-1261.86%	RSI (14)	53.46	Volatility	9.34% 7.93%
Optionable	Yes	Debt/Eq	0.64	EPS Q/Q	35.30%	Profit Margin	-1019.37%	Rel Volume	2.00	Prev Close	3.66
Shortable	Yes	LT Debt/Eq	0.47	Earnings	Aug 08 BMO	Payout	-	Avg Volume	136.30K	Price	4.02
Recom	1.00	SMA20	-0.35%	SMA50	8.37%	SMA200	23.90%	Volume	273,033	Change	9.84%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$4
Sep-18-20	Initiated	B. Riley FBR	Buy	$5
Feb-10-20	Initiated	SVB Leerink	Outperform	$6
Dec-10-19	Resumed	Cantor Fitzgerald	Neutral	$2 → $4
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$29 → $2
Jul-26-19	Downgrade	Mizuho	Buy → Neutral	$17 → $4
Jun-27-19	Initiated	Mizuho	Buy
Oct-12-18	Initiated	Mizuho	Buy	$17
Jun-05-18	Initiated	Seaport Global Securities	Buy	$29
Nov-08-17	Initiated	SunTrust	Buy	$26
Oct-16-17	Reiterated	H.C. Wainwright	Buy	$20 → $30
Oct-11-17	Reiterated	Cantor Fitzgerald	Overweight	$21 → $34
Oct-10-17	Initiated	Citigroup	Buy	$32
Oct-05-17	Reiterated	Maxim Group	Buy	$17 → $35
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$23
Jul-18-17	Reiterated	Maxim Group	Buy	$14 → $17
Jun-22-17	Resumed	Jefferies	Buy	$22
Jan-06-17	Initiated	Jefferies	Buy
Sep-29-16	Reiterated	Maxim Group	Buy	$8 → $14

Show Previous Ratings

Today 07:30AM	Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire) +9.84%
Sep-12-23 12:48PM	3 Biotech Blockbusters to Turn $5,000 Into $50,000 (InvestorPlace)
07:30AM	Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer (GlobeNewswire)
Sep-07-23 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-30-23 07:30AM	Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission (GlobeNewswire) +5.60%
07:41AM	Loading…
Aug-11-23 07:41AM	ABEO: On Track to File BLA in 3Q23... (Zacks Small Cap Research)
Aug-08-23 08:27AM	Abeona Therapeutics: Q2 Earnings Snapshot (AP Finance)
07:30AM	Abeona Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-28-23 07:30AM	Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023 (GlobeNewswire) +5.37%
Jul-19-23 08:30AM	Abeona Therapeutics Joins Rare Disease Company Coalition (GlobeNewswire)
Jul-07-23 08:30AM	Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jul-03-23 08:45AM	Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +6.95%
Jun-09-23 07:30AM	Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101 (GlobeNewswire)
Jun-01-23 07:30AM	Abeona Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 08:00AM	ABEO: Additional Phase 3 VIITAL Data Presented at ISID Meeting (Zacks Small Cap Research)
12:27AM	Loading…
May-25-23 12:27AM	Q1 2023 Abeona Therapeutics Inc Earnings Call and Portfolio Update Conference Call (Thomson Reuters StreetEvents)
May-22-23 07:30AM	Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023 (GlobeNewswire)
May-16-23 09:00AM	Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (GlobeNewswire)
May-13-23 08:15AM	Abeona Therapeutics First Quarter 2023 Earnings: US$0.54 loss per share (vs US$3.59 loss in 1Q 2022) (Simply Wall St.)
May-11-23 07:54AM	Abeona Therapeutics: Q1 Earnings Snapshot (AP Finance) -7.19%
07:30AM	Abeona Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
07:00AM	Abeona Therapeutics Announces Additional Phase 3 VIITAL Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting (GlobeNewswire)
Apr-18-23 07:15AM	ABEO: Initiating Coverage of Abeona Therapeutics Inc.; Using Gene Therapy to Treat Orphan Diseases (Zacks Small Cap Research)
Apr-10-23 07:30AM	Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (GlobeNewswire)
Mar-31-23 06:22AM	Companies Like Abeona Therapeutics (NASDAQ:ABEO) Could Be Quite Risky (Simply Wall St.)
Mar-29-23 07:30AM	Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-24-23 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants (GlobeNewswire) +11.52%
Mar-16-23 07:30AM	Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting (GlobeNewswire)
Mar-14-23 07:30AM	Abeona Therapeutics Announces Update on AAV Ophthalmology Program (GlobeNewswire)
Nov-14-22 07:30AM	Abeona Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -5.47%
02:28PM	Loading…
Nov-08-22 02:28PM	Cantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario' (Benzinga)
Nov-03-22 12:44PM	Abeona Therapeutics Touts Positive Data From Pivotal EB-101 Study In Blistering Skin Disorder (Benzinga) -13.23%
07:31AM	Abeona Therapeutics Announces $35 Million Private Placement Financing (GlobeNewswire)
07:30AM	Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL Study of EB-101 (GlobeNewswire)
Oct-19-22 07:30AM	Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire) -8.09%
Oct-04-22 07:30AM	Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire)
Sep-22-22 07:30AM	Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit (GlobeNewswire) -9.22%
Sep-13-22 07:30AM	Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference (GlobeNewswire)
Sep-08-22 08:48AM	10 Best Penny Stocks to Buy in September (Insider Monkey)
Aug-11-22 07:30AM	Abeona Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire) +12.02%
Jul-20-22 07:30AM	Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Jun-24-22 10:08AM	F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm (Zacks) -8.94%
Jun-13-22 01:27PM	FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy (Zacks) -6.18%
Jun-10-22 03:30PM	FDA Committee Recommends bluebird's (BLUE) CALD Therapy (Zacks)
Jun-08-22 01:21PM	bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy (Zacks) +8.49%
Jun-06-22 02:04PM	AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half (Zacks)
07:30AM	Abeona Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
Jun-01-22 02:25PM	BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug (Zacks) -7.84%
May-31-22 02:27PM	Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe (Zacks)
May-25-22 02:29PM	Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease (Zacks)
May-23-22 03:32PM	Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal (Zacks)
May-19-22 03:02PM	Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops (Zacks)
07:30AM	Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule (GlobeNewswire)
May-18-22 03:12PM	AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study (Zacks) -7.03%
11:47AM	Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate (Zacks)
May-17-22 09:27AM	AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug (Zacks)
08:00AM	Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics (GlobeNewswire)
May-13-22 07:30AM	Abeona Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-12-22 02:47PM	AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals (Zacks) +15.09%
May-11-22 02:28PM	Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates (Zacks) -14.69%
May-10-22 02:36PM	Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates (Zacks)
11:37AM	Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down (Zacks)
May-06-22 03:48PM	Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks) -9.37%
03:38PM	ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates (Zacks)
May-04-22 07:30AM	Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human Primates (GlobeNewswire)
May-03-22 07:00AM	Dianthus, a new $100M startup, aims to make autoimmune treatments easier (American City Business Journals)
Apr-29-22 09:00AM	Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire) -7.07%
07:30AM	Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock (GlobeNewswire)
Apr-19-22 10:51AM	Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth? (Simply Wall St.)
Mar-31-22 07:30AM	Abeona Therapeutics Announces Strategy Update and 2021 Financial Results (GlobeNewswire)
Mar-28-22 11:20AM	Abeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit (GlobeNewswire)
Mar-14-22 07:30AM	Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL Study of EB-101 in RDEB (GlobeNewswire)
Jan-25-22 10:00AM	Here's Why Abeona Therapeutics (ABEO) Looks Ripe for Bottom Fishing (Zacks) +7.57%
Dec-22-21 07:30AM	Abeona Therapeutics Issues Letter to Shareholders (GlobeNewswire)
Dec-17-21 09:00AM	Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants (GlobeNewswire) -39.97%
Dec-16-21 04:01PM	Abeona Therapeutics Announces Public Offering of Common Stock and Warrants (GlobeNewswire) -6.39%
Dec-02-21 07:25AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Nov-19-21 10:00AM	Down 15.2% in 4 Weeks, Here's Why Abeona Therapeutics (ABEO) Looks Ripe for a Turnaround (Zacks)
Nov-18-21 07:30AM	Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Education and Research of Epidermolysis Bullosa (GlobeNewswire) -9.76%
Nov-17-21 07:30AM	Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conference (GlobeNewswire)
Nov-16-21 07:30AM	Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-15-21 07:45AM	Abeona Therapeutics Reports Third Quarter Financial Results (GlobeNewswire)
07:12AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Oct-21-21 07:30AM	Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit (GlobeNewswire)
06:21AM	Abeona Therapeutics (NASDAQ:ABEO) investors are sitting on a loss of 90% if they invested three years ago (Simply Wall St.)
Oct-13-21 07:30AM	Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses (GlobeNewswire)
Oct-12-21 07:30AM	Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality (GlobeNewswire)
Sep-21-21 04:01PM	Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings (GlobeNewswire)
Sep-07-21 07:30AM	Abeona Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-10-21 07:30AM	Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer (GlobeNewswire)
Jul-28-21 04:01PM	Abeona Therapeutics Reports Second Quarter Financial Results (GlobeNewswire)
07:30AM	Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Jul-26-21 07:30AM	Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy (GlobeNewswire)
06:12AM	Abeona Reports Positive Data for Sanfilippo Syndrome Treatment (TheStreet.com)
Jul-23-21 07:30AM	Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL Study for Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire)
Jul-07-21 12:02PM	Abeona Unveils Additional Data From Gene Therapy Trial For Rare Connective Tissue Disorder (Benzinga)
07:30AM	Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting (GlobeNewswire)
Jun-14-21 10:00AM	10 Penny Stocks Robinhood Traders are Buying in 2021 (Insider Monkey)
Jun-02-21 07:30AM	Abeona Therapeutics to Present at Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-26-21 07:30AM	Abeona Therapeutics Issues Letter to Stockholders (GlobeNewswire) +10.74%

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Amoroso Michael	Director	Sep 20	Sale	3.90	327	1,275	114,465	Sep 22 04:05 PM
Vazzano Joseph Walter	Chief Financial Officer	Sep 19	Buy	3.82	3,000	11,458	238,179	Sep 20 09:00 AM
O'Malley Brendan M.	SVP, General Counsel	Sep 18	Buy	3.80	3,000	11,400	187,421	Sep 19 09:00 AM
Amoroso Michael	Director	Jun 20	Sale	4.45	338	1,504	114,792	Jun 21 04:05 PM
Alvino Mark	Director	Apr 25	Sale	3.25	887	2,883	17,527	May 05 04:05 PM
Amoroso Michael	Director	Mar 20	Sale	2.33	268	624	56,441	Mar 21 05:13 PM
Amoroso Michael	Director	Mar 03	Sale	2.38	1,002	2,385	56,709	Mar 03 07:06 PM
O'Malley Brendan M.	SVP, General Counsel	Dec 09	Buy	3.13	5,869	18,370	93,830	Dec 12 04:10 PM
O'Malley Brendan M.	SVP, General Counsel	Nov 18	Buy	3.99	7,500	29,925	87,961	Nov 21 09:00 AM
Vazzano Joseph Walter	Chief Financial Officer	Nov 18	Buy	4.00	2,500	10,000	95,250	Nov 21 09:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABEO | Abeona Therapeutics Inc

Upgrade your FINVIZ experience